CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.

Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.